FCM
KRSA

Farallon Capital Management’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Farallon Capital Management’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,500
Closed -$952K – 107
2019
Q4 		$952K Sell
2,500
-190
-7% -$17.7K 0.01% 116
2019
Q3 		$4.57M Sell
2,690
-1,196
-31% -$258K 0.03% 90
2019
Q2 		$6.23M Buy
+3,886
New +$1.1M 0.04% 92

Other funds holding KRSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Farallon Capital Management's KRSA Position: Q1 2020 in Review

Farallon Capital Management sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q1 2020, closing a stake of 2,500 shares — an estimated $952K sold.

Farallon Capital Management first reported a position in KRSA in Q2 2019 and held it in 3 quarters. The position peaked at $6.23M in Q2 2019. 74 funds tracked by Wall St. Rank hold KRSA as of Q1 2020.

  • Farallon Capital Management reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Farallon Capital Management sold 2,500 Korsana Biosciences, Inc. Common Stock shares in Q1 2020, an estimated $952K.
  • Farallon Capital Management first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 3 quarters.
  • Farallon Capital Management's Korsana Biosciences, Inc. Common Stock position peaked at $6.23M in Q2 2019.
  • 74 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q1 2020.

Based on Farallon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.